uploads///rawpixel com  unsplash

How Analysts View Tetraphase Pharmaceuticals in April 2018

By

Updated

Company overview

Tetraphase Pharmaceuticals (TTPH) is a clinical-stage biopharmaceutical company focused on creating novel antibiotics. These antibiotics treat serious and life-threatening multidrug-resistant infections by using the company’s proprietary chemistry technology. Its lead product candidate is eravacycline, which is being developed as an intravenous antibiotic.

Article continues below advertisement

Analysts’ recommendations

Of the eight analysts covering Tetraphase Pharmaceuticals (TTPH) in April 2018, one analyst gave the stock a “strong buy” rating, six analysts gave it a “buy” rating, and one analyst gave the stock a “hold” rating. The mean rating for the stock is 2.0 with a target price of $7.00.

Peer ratings      

Of the 22 analysts covering Pfizer (PFE) in April 2018, two analysts gave the stock a “strong buy” rating, and nine analysts gave it a “buy” rating. Nine analysts gave Pfizer a “hold” rating, and two analysts gave it a “strong sell” rating. The mean rating for the stock is ~2.6 with a target price of $40.11.

Of the 20 analysts covering Spark Therapeutics (ONCE) in April 2018, four analysts gave the stock a “strong buy” rating, and ten analysts gave it a “buy” rating. Five analysts gave the stock a “hold” rating, and one analyst gave it a “strong sell” rating. The mean rating for the stock is 2.2 with a target price of $70.05.

Of the 23 analysts covering BioMarin Pharmaceutical (BMRN) in April 2018, eight analysts gave the stock a “strong buy” rating, 11 analysts gave it a “buy” rating, and four analysts gave BMRN a “hold” rating. The mean rating for the stock is ~1.8 with a target price of $114.30.

In the next part of this series, we’ll take a look at Tetraphase Pharmaceuticals’ product pipeline.

Advertisement

More From Market Realist